On December 22, 1988, a second conjugate vaccine was licensed by the US Food and Drug Administration for the prevention of infections caused by H influenzae type b in children 18 months of age or older. This newly licensed vaccine is a conjugate of H influenzae type b capsular oligosaccharide and a nontoxic mutant diphtheria toxin protein molecule called CRM197. The official designation of this vaccine is 'Haemophilus b conjugate vaccine (diphtheria CRM197 protein conjugate)' and it is often referred to as HbOC.
|Original language||English (US)|
|Number of pages||2|
|State||Published - 1989|
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health